Jan 10 |
Organon says Xaciato now available nationwide
|
Jan 4 |
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
|
Jan 4 |
When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?
|
Dec 26 |
Dare Bioscience secures $12M in royalty-backed investment structure
|
Dec 26 |
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
|
Dec 20 |
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
|
Dec 13 |
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
|
Dec 7 |
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy Associated with Menopause
|
Dec 4 |
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
|
Nov 23 |
20 Countries with the Highest Teenage Pregnancy Rates
|